Linsitinib is an oral small molecule that inhibits the activity of insulin-like growth factor-1 receptor (IGF-1R). It is believed that inhibition of IGF-1R may help reduce orbital inflammation and ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding ...

Four-month regimen recommended for drug-susceptible TB and six-month regimen recommended for drug-resistant TB ...

Reductions seen in median Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome score, Patient Assessment of Gastrointestinal Symptom Severity Index ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...

Use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially over-the-counter formulations, and certain other drug classes are among the risk factors for community-acquired acute kidney injury (CA ...

(HealthDay News) — Overall, 15.4% of children aged 0 to 35 months receive an invalid vaccine dose, receiving a vaccine earlier or later than recommended, according to a study published online Jan. 10 ...

It is quite common for hospitals to hire physicians, particularly emergency department physicians, as independent contractors, rather than employees, in order to reduce the chances for legal liability ...

There are currently no FDA-approved treatments for FXS, a disease that affects approximately 1 in 4-5000 men and 1 in 6-8000 women globally.

SCORPIO machine learning system can predict certain outcomes across diverse cancer types and health care settings ...